Peer-influenced content. Sources you trust. No registration required. This is HCN.

Evolving Strategies for the Management of Core-Binding Factor Acute Myeloid Leukemia (AML)

In this Q&A, Dr. Gautam Borthakur from the University of Texas MD Anderson Cancer Center talks with Clinical Advances in Hematology & Oncology about the goals, treatment options (including tailored treatment), differences in de novo vs. therapy-related, and other suggestions in patients with core-binding factor acute myeloid leukemia (AML).

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form